Use of modified RECIST criteria to improve response assessment in targeted therapies: challenges and opportunities.

摘要

The Response Evaluation Criteria in Solid Tumors (RECIST) is a methodology for standardizing the reporting of therapeutic response categories in cancer patients. It has served as the standard of imaging-based assessment of cancer response to therapy in clinical trials and in basic clinical practice. Since its inception in 2000, the RECIST standard has been adopted throughout the worldwide oncologic community as the basis of establishing imaging response of cancer to therapy.